Is TG103 Approved? Phase 3 Status and What Comes Next (2026)
No. TG103 is still a Phase 3 asset. It is advanced enough to matter, but it still belongs in the pipeline rather than the approved-product bucket.
Current stage
Phase 3
Approval read
Not approved for broad US obesity use.
Likely window
2027 to 2028 depending on filing strategy and geography.
Next step
Convert late-stage advancement into a clearer filing and market-relevance story.
Direct answer
No. TG103 is still a Phase 3 asset. It is advanced enough to matter, but it still belongs in the pipeline rather than the approved-product bucket.
Status facts for search and AI answers
What this TG103 status page answers
Compound
TG103
TG103 is tracked as a GLP-1 Fc-fusion program from CSPC Pharma.
Approval read
Not approved for broad US obesity use.
No. TG103 is still a Phase 3 asset. It is advanced enough to matter, but it still belongs in the pipeline rather than the approved-product bucket.
Likely window
2027 to 2028 depending on filing strategy and geography.
The likely window is a FormBlends tracking read, not a guarantee of patient access.
Next step
Convert late-stage advancement into a clearer filing and market-relevance story.
This is the milestone most likely to change the page's answer.
Decision path
What does TG103's status mean for access?
TG103's approval status should be read as a regulatory signal, not a shortcut to buying or prescribing. The useful decision is whether this is approved, decision-stage, investigational, or simply worth monitoring.
- Compound
- TG103
- Stage
- Phase 3
- Approval read
- Not approved for broad US obesity use.
- Window
- 2027 to 2028 depending on filing strategy and geography.
Step 1
Classify availability
Phase 3 next-generation GLP-1 program with advanced status but relatively low Western mindshare.
Read compound pageStep 2
Watch required milestone
Convert late-stage advancement into a clearer filing and market-relevance story.
Open pipeline trackerStep 3
Use current-care rules
If you need care now, separate trial-stage news from provider-reviewed GLP-1 options that can actually be prescribed.
Compare care routesWhat the status means now
Phase 3 next-generation GLP-1 program with advanced status but relatively low Western mindshare.
TG103 matters because later-stage GLP-1 variants outside the usual US spotlight can still shape pricing and competition later.
What needs to happen next
Convert late-stage advancement into a clearer filing and market-relevance story.
What FormBlends is watching
- Whether Phase 3 progress becomes globally visible
- How the Fc-fusion angle is positioned commercially
- Whether the sponsor pushes for broader relevance
What could delay the timeline
- Weak visibility despite advanced stage
- A fragmented filing strategy
- Difficulty standing out from stronger-known late-stage names